Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGL | P35573 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 8/20 | 0.61 |
| ▸ | MGAM | O43451 | 4/20 | 0.61 |
| ▸ | SI | P14410 | 3/20 | 0.61 |
| ▸ | GBA1 | P04062 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | LCT | P09848 | 1/20 | 0.61 |
| ▸ | GBA2 | Q9HCG7 | 8/20 | 0.53 |
| ▸ | UGCG | Q16739 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124249 | 1.00 | AGL (0.69) | AGLGAAMGAMSIGBA1 | |
| SCHEMBL9485658 | 1.00 | AGL (0.69) | AGLGAAMGAMSIGBA1 | |
| SCHEMBL2270637 | 0.93 | GAA (0.70) | AGLGAAMGAMSIGBA1 | |
| SCHEMBL2274019 | 0.91 | GAA (0.68) | AGLGAAMGAMSIGBA1 | |
| SCHEMBL13848050 | 0.82 | AGL (1.00) | AGLGAAMGAMSIGBA1 | |
| SCHEMBL2435218 | 0.82 | AGL (1.00) | AGLGAAMGAMSIGBA1 | |
| SCHEMBL6135753 | 0.82 | AGL (1.00) | AGLGAAMGAMSIGBA1 | |
| SCHEMBL6135379 | 0.82 | AGL (1.00) | AGLGAAMGAMSIGBA1 | |
| SCHEMBL6135638 | 0.79 | GBA1 (0.61) | AGLGAAMGAMSIGBA1 | |
| SCHEMBL6135119 | 0.79 | AGL (0.71) | AGLGAAMGAMSIGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785178-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2785346-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2768307-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2720539-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2013081642-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013082000-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013058809-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012174064-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012134971-A2 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-2442644-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-1711174-A1 | ADJUVANT COMPOSITIONS | M N L Pharma Limited (GB) | 2006-10-18 | — | — | EP | disclosed |
| EP-1711176-A1 | IMMUNOMODULATORY ALKALOIDS | M N L Pharma Limited (GB) | 2006-10-18 | — | — | EP | disclosed |
| WO-2006077427-A2 | ANTIVIRAL DRUG COMBINATIONS | MNL PHARMA LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2005070415-A1 | ADJUVANT COMPOSITIONS | M N L PHARMA LIMITED (GB) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070418-A1 | IMMUNOMODULATORY ALKALOIDS | M N L PHARMA LIMITED (GB) | 2005-08-04 | — | — | WO | disclosed |
| EP-1210082-A2 | LONG CHAIN N-ALKYL COMPOUNDS AND OXA-DERIVATIVES THEREOF AND USE AS ANTIVIRAL COMPOSITIONS | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001010429-A2 | LONG CHAIN N-ALKYL COMPOUNDS AND OXA-DERIVATIVES THEREOF AND USE AS ANTIVIRAL COMPOSITIONS | THE CHANCELLOR, MASTERS, AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2001-02-15 | — | — | WO | disclosed |
| US-5352591-A | Intermediates for enzyme inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-10-04 | — | — | US | disclosed |
| US-5229523-A | Glycosidase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-07-20 | — | — | US | disclosed |
| WO-1992021655-A2 | 2-METHYL-5-HYDROXYMETHYL- AND 2,5-DIMETHYL-3,4-DIHYDROXYPYRROLIDINES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1992-12-10 | — | — | WO | disclosed |